TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in stem cell numbers in blood circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and local tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of intraoperative Mean Arterial Pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Masseters EMG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: thickness of cementum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients who proceed to radical cystectomy and pelvic lymph node dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: grade of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: grade of neck dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in healing response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bleeding Category
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of subjects who experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total Young Mania Rating Scale (YMRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to doubling of serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: end stage renal disease (ESRD)
Endpoint domain: Mortality/survival
Primary endpoint: Number of ECG Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Laboratory Abnormalities of Safety Biomarkers: d-Dimer and Thrombin Anti-Thrombin (TAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Topiramate plasma concentration-time profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal Cancer (CRC) Screening Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Colorectal Cancer (CRC) Screening Intention: Change From Baseline to Post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Type of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Need for ancillary procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correlation coefficients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Narcotic Use Postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in tumor size and burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of correct endotracheal tube (ETT) position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma concentrations of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative Incidence of Functional Decline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Experiencing at Least One Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of CLE-EMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of tivozanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Behavior Checklist score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Successful Lesion Creation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 5 km run time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iatrogenic complications
Endpoint domain: Adverse events/effects
Primary endpoint: number of harvested lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of post-operative pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Weight for Age Z-Score (WAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Height for Age Z-Score (HAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in nasal secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in sneezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of edema of the nasal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decreased frequency of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease the frequency of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of nasal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postprandial Glycemic Incremental Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Lower esophageal sphincter pressure (LES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in frequency of dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in frequency of Regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HBV reactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Immunomodulatory effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in ONLS sumscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Leiter Test of Sustained Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kiddie Continuous Performance Test (kCAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peabody Picture Vocabulary Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Day-Night Stroop Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum observed plasma drug concentration (Cmax) post-dose - Levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t) - Levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half-life (t1/2) - Levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in average score on the Leicester Cough Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CT diagnostic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral chemosensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic complete response (PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Memory Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Control Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hand function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fresh frozen plasma consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pressure ulcer occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Longitudinal change in PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Detection of misoprostol in urine sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-relapse mortality (NRM) at 200 days
Endpoint domain: Mortality/survival
Primary endpoint: Intrasinus bone formation around implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Body weight Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass Index measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring Blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participants acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evaluate the dropout among participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participants satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Skeleton-related event
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Acquisition Time Product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Efficacy of One-day Rest/Stress BMS747158 PET MPI Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Efficacy of One-day Rest/Stress BMS747158 PET MPI Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Algometric pressure threshold scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Workplace sitting time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of platelet lysate injection
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of Future Product Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to Placebo Products
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Grade 2+ Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Worst Pain Measurement Via Numeric Rating Scale (NRS-11)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic Usage During Medication Abortion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood flow in the umbilical cord or skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Myotube diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding on probing changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Brain-Derived Blood Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Ocular-Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absolute change in Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual differences from normal brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in maximal voluntary contraction of the hip flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of exacerbation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced At Least One Postoperative Infectious Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Empyema
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Clostridium (C) Difficile Colitis
Endpoint domain: Adverse events/effects
Primary endpoint: arterial CO2 partial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sweet taste sensitivity and perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: z-BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Posttraumatic Stress Disorder (PTSD) Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maintenance of remission in Crohn's disease and ulcerative colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intravascular Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definitive cure based on parasitological clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty survey score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency to Sleep Onset After Middle-of-the-Night Awakening
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Blood Pressure Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Six-minute Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of antimicrobials expressed as DDD per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 12-lead electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in glycemic variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nurse Visit Participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-scan change of DTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of clinical type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in prevalence of MRSA carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intermittent Hypoxemia Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in sustained attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in executive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic sensitivity for malaria parasite detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnostic specificity for malaria parasite detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Self assessment score of patient centred care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of molecular fluorescence endoscopy using Cetuximab-800CW
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of molecular fluorescence-guided surgery using Cetuximab-800CW
Endpoint domain: Adverse events/effects
Primary endpoint: Nocturnal enuresis resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of FVIII (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion from aMCI to AD
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of the Clinical Global Impression (CGI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for other uterotonics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Local control time
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With PA-negative Cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 10 Repetition Maximum (RM) for knee flexor, knee extensor, hip abductor, low row
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Specific Functional Scale (PSFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time elapsed from A&E presentation to study recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time elapsed from A&E presentation to initial MRI or x-ray investigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time elapsed from A&E presentation to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ART Adherence at 20 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral Load Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Index of Severity of Fibromyalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion (vulvar HSIL or wart) size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage clearance of vulvar HSIL lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with all vulvar HSIL lesions cleared
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refrain from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of PKUM model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Treatment Sessions Attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bilateral kidney RI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Best Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional DRD2/3 Binding Percent Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of asymptomatic carotid artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Natural history of stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: potential patient versus
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Plasma concentration of Levetiracetam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence of sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of sequelae
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Heart rate variability (HRV RMSSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serotonin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Objective response rate (ORR) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mental functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning